¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"vascular structure"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • vascular murmur
    Ç÷°üÀâÀ½
  • vascular permeability factor
    Ç÷°üÅõ°úÀÎÀÚ
  • vascular purpura
    Ç÷°üÀÚ»ö¹Ý
  • vascular reflex
    Ç÷°ü¹Ý»ç
  • vascular resistance
    Ç÷°üÀúÇ×
  • vascular ring
    Ç÷°ü°í¸®, Ç÷°ü·û
  • vascular sclerosis
    µ¿¸Æ°æÈ­Áõ
  • vascular spider
    °Å¹Ì¸ð¾çÇ÷°ü
  • vascular system
    Ç÷°ü°èÅë, Ç÷°ü°è
  • vascular tone
    Ç÷°ü±äÀåµµ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • vascular permeability factor
    Ç÷°üÅõ°úÀÎÀÚ
  • inner vascular web
    ³»Ç÷°ü¸Á
  • vascular lamina
    ¸Æ°üÆÇ
  • vascular layer
    ¸Æ°üÃþ, Ç÷°üÃþ
  • vascular murmur
    Ç÷°üÀâÀ½
  • vascular cell adhesion molecule
    Ç÷°ü¼¼Æ÷À¯ÂøºÐÀÚ
  • reticulate vascular nevus
    ±×¹°Ç÷°ü¸ð¹Ý
  • peripheral vascular resistance
    ¸»ÃÊÇ÷°üÀúÇ×
  • pulmonary vascular resistance
    ÇãÆÄÇ÷°üÀúÇ×, ÆóÇ÷°üÀúÇ×
  • vascular purpura
    Ç÷°üÀÚ»ö¹Ý
  • vascular reflex
    Ç÷°ü¹Ý»ç
  • vascular resistance
    Ç÷°üÀúÇ×
  • vascular ring
    Ç÷°ü°í¸®
  • vascular sclerosis
    (¢¡arteriosclerosis) µ¿¸Æ°æÈ­Áõ
  • vascular spider
    °Å¹ÌÇ÷°ü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • nuclear structure
    ÇÙ±¸Á¶
  • palindrome [structure]
    ÆÈ¸°µå·Ò, ¾ÕµÚ»óµ¿ ¿°±â¼­¿­
  • personality structure, Jungian theory
    Àΰݱ¸Á¶
  • primary structure
    ÀÏÂ÷±¸Á¶(¡­Ï°ðã).
  • pseudoknot RNA structure
    ¸ÅµìÇü RNA ±¸Á¶
  • quasicrystalline structure
    ÁذáÁ¤±¸Á¶(ñÞÌ¿ïÜϰðã).
  • resonance structure
    °ø¸í±¸Á¶(Íìٰϰðã).
  • secondary structure
    ÀÌÂ÷±¸Á¶(¡­Ï°ðã).
  • structure
    ±¸Á¶
  • structure activity relationship
    ±¸Á¶-Ȱ¼ºµµ°ü°è.
  • structure activity relationship
    (È­ÇÐ)±¸Á¶ Ȱ¼º »ó°ü°ü°è
  • structure of bone
    »À±¸Á¶
  • structure of personality
    Àΰݱ¸Á¶(ìÑ̫ϰðã).
  • tertiary structure
    »ïÂ÷±¸Á¶(ß²ó­Ï°ðã).
  • typical structure
    ÀüÇüÀû±¸Á¶
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
hfs hyperfine structure
LFS lateral facet syndrome; Li-Fraumeni syndrome; limbic forebrain structure; liver function series
MTS Medicare transaction system; magnetization transfer contrast; methotrexate; multicellular tumor sphe...
QSAR quantitative structure-activity relationship
ROPS rollover protective structure
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
SCID Structure Clinical Interview for DSM-III-R
SFM Structure-from-motion
3-D-QSAR Three-dimensional quantitative structure-activity relationship
XAFS X-Ray Absorption Fine Structure
XANES X-ray Absorption Near Edge Structure
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • hepatic vascular resistance
    °£ Ç÷°ü ÀúÇ×
  • mixed muscular vascular headache
    ±Ù¸Æ°ü¼º È¥ÇÕ µÎÅë, È¥ÇÕµÈ ±Ù-Ç÷°ü¼º µÎÅë, È¥ÇÕ¼º ±ÙÀ° Ç÷°ü µÎÅë, È¥ÇÕÇü ±Ù¸Æ°ü¼º µÎÅë
  • multiple vascular tumor
    ´Ù¹ß¼º Ç÷°ü Á¾¾ç
  • non-vascular intracranial disorder
    ºñÇ÷°ü¼º µÎ°³³» Àå¾Ö
  • peripheral vascular disease
    ¸»ÃÊÇ÷°ü Áúȯ
  • peripheral vascular system
    ¸»ÃÊÇ÷°ü°è
  • renal vascular injury
    ½Å Ç÷°ü ¼Õ»ó
  • vascular
    ¸Æ°ü¼º, Ç÷°ü¼º
    Ç÷°ü¿¡ °üÇÑ. ¸Æ°üÀÇ, Ç÷°üÀÇ, Ç÷°üºÐÆ÷¼ºÀÇ. ´Ù·®ÀÇ Ç÷¾× °ø±ÞÀÌ Ç³ºÎÇÔÀ» ³ªÅ¸³»´Â.
  • vascular access
    Ç÷°ü Á¢±Ù
    Ç÷°ü Áúȯ ½Ã Áúȯ ºÎÀ§¿¡ µµ´ÞÇϱâ À§ÇÑ Á¢±Ù. ¶Ç´Â Àå±â³ª ±â°ü µîÀÇ ¼ö¼úÀ» À§ÇØ Ç÷°üÀ» ÅëÇØ º´¼Ò¿¡ µµ´ÞÇÏ´Â Á¢±Ù.
  • vascular bed
    Ç÷°ü»ó
  • vascular cecal fold
    ¸·Ã¢ÀÚ Ç÷°ü ÁÖ¸§
  • vascular change
    ¸Æ°ü¼º º¯È­
  • vascular damage
    Ç÷°ü ¼Õ»ó
  • vascular disorder
    Ç÷°ü Àå¾Ö, Ç÷°ü¼º Àå¾Ö
  • vascular endothelial growth factor
    ¸Æ°ü ³»ÇǼ¼Æ÷ ¼ºÀå ÀÎÀÚ, Ç÷°ü ³»ÇǼ¼Æ÷ ¼ºÀå ÀÎÀÚ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
acute vascular purpura <dermatology> This relatively rare disorder is characterised by skin purpura, joint pains, abdominal pain and renal disease (glomerulonephritis).
Although Henoch-Schonlein purpura or anaphylactoid purpura, is thought to be a immune complex mediated disease, its exact cause is unknown. Its typical benign coarse can, however, include renal failure.
(27 Sep 1997)
articular vascular circle An anastomosis of vessels encircling a joint.
See: articular vascular network.
Synonym: circulus articularis vasculosus.
(05 Mar 2000)
articular vascular network A vascular rete in the neighborhood of a joint, where such arrangements are common, enabling a collateral circulation by which blood will be supplied distal to the joint regardless of compromises resulting from joint position.
Synonym: circulus articularis vasculosus, rete vasculosum articulare, articular network.
(05 Mar 2000)
articular vascular network of elbow Vascular networks in the region of the elbow, composed of anastomoses between branches of the radial and middle collateral, superior and inferior ulnar collateral, radial recurrent, interosseous recurrent, and recurrent ulnar arteries.
Synonym: rete articulare cubiti.
(05 Mar 2000)
articular vascular network of knee An arterial network over the front and sides of the knee, formed by branches of the descending genicular artery, of the five genicular arteries from the popliteal, of the anterior tibial recurrent, and of the fibular circumflex branch of the posterior tibial.
Synonym: rete articulare genus.
(05 Mar 2000)
atherosclerotic vascular disease <cardiology> The progressive narrowing and hardening of the arteries over time. This is known to occur to some degree with aging, but other risk factors that accelerate this process have been identified.
These factors include: high cholesterol, high blood pressure, smoking, diabetes and family history for atherosclerotic disease.
(27 Sep 1997)
blood-vascular system The heart and the blood vessels by which blood is pumped and circulated through the body.
(12 Dec 1998)
vascular <physiology> Pertaining to blood vessels or indicative of a copious blood supply.
(18 Nov 1997)
vascular anticoagulant <protein> Group of calcium-binding proteins that interact with acidic membrane phospholipids in membranes. They contain 4 or 8 repeats of a 61 amino acid domain that folds into 5 a helices.
Also known by several other names (e.g. Lipocortins, endonexins), reflecting the history of their discovery in different contexts.
See: lipocortin, endonexin I & II, calpactin, p70 and calelectrin.
(18 Nov 1997)
vascular bud An endothelial sprout arising from a blood vessel.
(05 Mar 2000)
vascular bundle Strand of vascular tissue in a plant, composed of xylem and phloem.
(18 Nov 1997)
vascular cambium Lateral meristem that forms the secondary tissue and is located between the xylem and phloem.
(09 Oct 1997)
vascular capacitance The relationship between the volume of blood contained within a segment of vasculature and the pressure distending the vascular walls over a wide range of pressures and volumes. The veins of the body are not only conduits for the return of blood to the right heart, but they also determine most of the vascular capacitance and contain most of the blood volume. Changes in vascular capacitance provide a quick and effective mechanism for the filling of the right heart, thereby influencing cardiac output. Vascular capacitance is somewhat analogous to vascular resistance but whereas vascular resistance relates to flow through a blood vessel, vascular capacitance relates to the volume contained in it.
(12 Dec 1998)
vascular cataract Congenital cataract in which the degenerated lens is replaced with mesodermal tissue.
Synonym: cataracta adiposa, cataracta fibrosa.
(05 Mar 2000)
vascular cell adhesion molecule-1 Cytokine-induced cell adhesion molecule present on activated endothelial cells, tissue macrophages, dendritic cells, bone marrow fibroblasts, myoblasts, and myotubes. It is important for the recruitment of leukocytes to sites of inflammation.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á